Singapore markets open in 5 hours 5 minutes

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
339.64+11.29 (+3.44%)
As of 3:55PM EDT. Market open.
Sign in to post a message.
  • H
    Herman
    bought this when it was 100 now triple the stock price now holding on for life
  • s
    sniper
    350 at closing today?
    what do you guys think?
  • K
    Kenneth
    .. HOT of The Press .. Berenberg Bank adjusts PT to $400 from $235 ..
  • C
    C
    "In a report released today, Zhiqiang Shu from Berenberg Bank reiterated a Buy rating on BioNTech SE, with a price target of $400.00. The company’s shares closed last Friday at $328.35, close to its 52-week high of $331.00."

    https://www.analystratings.com/articles/analysts-offer-insights-on-healthcare-companies-regeneron-nasdaq-regn-argenx-se-nasdaq-argx-and-biontech-se-nasdaq-bntx/
  • B
    Burkhard
    I have the honor to proudly present yet another.....(GLTA)
  • B
    Burkhard
    I need a backup for September. I am on holiday for a week. Any volunteers? Alex?
  • x
    ximenezxim
    Was it neccesary to increase prices? Nonetheless BNTX shall rise very strongly from here to Earnings now two weeks away and $400 per piece will be a "fing of the fast".
  • T
    Tozinameran
    All Time High in Frankfurt
  • B
    Burkhard
    BioNTech creates 500 new jobs

    Status: 08/01/2021 11:34 a.m.

    BioNTech has grown strongly since the beginning of the pandemic. Now the Mainz biotechnology company has advertised numerous other positions "across all departments". The focus is on sales.The Mainz corona vaccine manufacturer BioNTech is expanding. According to a report by "Welt am Sonntag", the company said that an extensive job creation is planned for the coming months. 500 new positions across all departments are currently advertised. Before the corona pandemic, BioNTech employed a good 1,300 people.

    The company worked primarily on new therapies for cancer. Together with the US company Pfizer, BioNTech then developed the first vaccine against the coronavirus approved in many countries last year. To do this, the company used the new mRNA technology, which is also used in the development of cancer immunotherapies. BioNTech recently announced that it wanted to develop a malaria vaccine.Number of employees has grown in pandemicIn the past year and a half, the number of BioNTech employees has already risen to around 2000. According to the "Welt am Sonntag" report, the manufacturer now wants to invest in its own sales team of 60 employees for the first time in order to promote the marketing of approved products itself."We set up BioNTech as a fully integrated company from the start. With our own research and development, production and now also sales," said board member Sierk Poetting of the newspaper.

    https://www.tagesschau.de/wirtschaft/unternehmen/biontech-expansion-101.html
  • T
    Tozinameran
    Closing in on Moderna 😎
  • L
    Lobstah
    Also, from Beijing's Xinhua News Agency today 8/2/21 (edited)

    It sounds like they need to work on their mathematics logic a little better, but whatever, our booster will come to their rescue very soon.

    The Delta variant is estimated to be almost twice as transmissible as the original strain. It spreads much faster and is more likely to induce severe symptoms among patients, said Feng Zijian, a researcher at the Chinese Center for Disease Control and Prevention…
    Nevertheless, similar to the recent resurgence of coronavirus in Guangzhou, which was also triggered by the highly contagious Delta variant, most patients in this outbreak have shown mild symptoms, said Zhong…
    Preliminary studies on Guangzhou's latest COVID-19 outbreak show that China's domestic vaccines prove effective to protect its people against the Delta variant, Zhong added...
    The protective effect of China's domestic vaccines is 100 percent effective against severe cases, 76.9 percent against moderate cases, 67.2 percent against mild ones, and 63.2 percent against asymptomatic carriers accordingly…
    Building a herd immunity is needed to combat the Delta variant, which can be achieved with around an 83.3-percent vaccination rate in China, said the expert.
  • v
    von Liebenstein
    My dear BionTech friends, for anyone who's trading with leverage, I suggest gearing up, because we have a beautiful ride towards $400,- ahead of us upcoming week!
  • e
    eastling
    BioNTech SE ($BNTX) will announce its financial results for the second quarter on Monday, August 9th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2021.With all the crazy things going on and my limited time/ability to day trade I have found https://stockhaul.today/j2k79w useful
  • M
    Md
    BioNTech was founded by Şahin and his wife. And despite seeing his net worth climb astronomically over the past year, he has yet to sell a share.
  • T
    TBONE
    Can somebody answer that phone? Oh, sorry, it’s the cash register
  • B
    Bala2020
    What are the chances to see 360$ this week? Does the increase in vaccine prices and 3rd booster jab in the EU can result in more buying, due to more revenue in further quarter?
  • D
    Dick
    An observation FWIW. With over 2 million shares traded in the first hour it is now obvious that a few institutions and large investors are entering. They do not like to pay retail. Thus the share price was pushed down $15 from the opening minutes high. It is bouncing now.
  • m
    man
    Moderna don't go to breakthrough $400. This is the sign of peak.
    BNTX is too expensive and all good news shown.
    Profit taking at least 10-15%.
    So. the safe buying zone is $310-290 now.
  • B
    Burkhard
    See you later with a good old GIF
  • L
    Lobstah
    To all longs...I expect a very rough share price highway with wild swings for the next month or two because of the new increases in mRNA vaccine sell points. Our EU pricing is now up to 19.50 euros vs 15.50 euros before. Moderna similar. The outcry will be loud once more for sharing our IP and world voices calling for the pharma bigs heads on a monopoly platter. Be careful of market timing knee-jerk reactions and institutional bottom fishing because it will happen. Know what you own and why you own it.